Lifeward LTD. (LFWD) — SEC Filings

Overview

Lifeward LTD. (LFWD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a D filed on Apr 2, 2026: Lifeward Ltd. filed a Form D on April 2, 2026, to announce an exempt offering of securities. The company, located at 2 Cabot Road, Hudson MA 01749, is in the business of Orthopedic, Prosthetic & Surgical Appliances & Supplies.

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 3 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Lifeward LTD. is neutral.

Filing Type Overview

Lifeward LTD. (LFWD) has filed 1 D, 22 8-K, 3 DEF 14A, 6 10-Q, 2 S-1/A, 2 S-1, 2 10-K, 1 8-K/A, 3 DEFA14A, 1 10-K/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (43)

• Lifeward Ltd. Files Form D for Securities Offering — D · Apr 2, 2026 Risk: medium
  Lifeward Ltd. filed a Form D on April 2, 2026, to announce an exempt offering of securities. The company, located at 2 Cabot Road, Hudson MA 01749, is in the bu
• Lifeward Ltd. Files 8-K — 8-K · Mar 31, 2026 Risk: low
  Lifeward Ltd. filed an 8-K on March 31, 2026, reporting other events as of March 30, 2026. The filing does not contain specific financial details or significant
• Lifeward Ltd. Reports Board and Compensation Changes — 8-K · Dec 19, 2025 Risk: low
  Lifeward Ltd. announced on December 17, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depar
• Lifeward Seeks Reverse Stock Split, Capital Increase Approval — DEF 14A · Dec 1, 2025 Risk: medium
  Lifeward Ltd. (LFWD) is convening an Extraordinary General Meeting of Shareholders on January 6, 2026, to address critical corporate structure changes. The prim
• Lifeward's Q3 Loss Widens Amid Revenue Dip, Cash Burn — 10-Q · Nov 14, 2025 Risk: high
  Lifeward Ltd. (LFWD) reported a net loss of $14.566 million for the nine months ended September 30, 2025, an increase from the $13.664 million net loss in the p
• Lifeward Ltd. Files 8-K on Operations — 8-K · Oct 16, 2025 Risk: low
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed an 8-K on October 16, 2025, to report on its results of operations and financial condition. The company, inc
• Lifeward's Net Loss Widens to $11.4M Amid Revenue Dip, Impairment Charge — 10-Q · Aug 14, 2025 Risk: high
  Lifeward Ltd. (LFWD) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $11.396 million, up from $10.580 million in th
• Lifeward Ltd. Files 8-K on Executive Changes and Financials — 8-K · Aug 13, 2025 Risk: medium
  Lifeward Ltd. filed an 8-K on August 13, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certai
• Lifeward Ltd. Faces Delisting Notice — 8-K · Aug 8, 2025 Risk: high
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed an 8-K on August 8, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or
• Lifeward Ltd. Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Aug 5, 2025 Risk: medium
  On August 1, 2025, Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed an 8-K report detailing several key events. The company announced the departure of a dire
• Lifeward Ltd. Signs Material Definitive Agreement — 8-K · Jun 26, 2025 Risk: medium
  On June 25, 2025, Lifeward Ltd. (formerly ReWalk Robotics Ltd.) entered into a material definitive agreement. The company, which specializes in orthopedic, pros
• Lifeward Files S-1/A for Continuous Public Offering — S-1/A · Jun 25, 2025 Risk: medium
  Lifeward Ltd. (LFWD) filed an S-1/A on June 25, 2025, indicating a proposed delayed or continuous public offering of securities under Rule 415. The company, for
• Lifeward Files S-1 for Future Capital Raises — S-1 · Jun 20, 2025 Risk: medium
  Lifeward Ltd. (LFWD) filed an S-1 registration statement on June 20, 2025, for a delayed or continuous offering of securities under Rule 415. The company, forme
• Lifeward Ltd. Reports Board & Executive Compensation Changes — 8-K · Jun 16, 2025 Risk: low
  Lifeward Ltd. announced on June 15, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certain offi
• Lifeward Ltd. Announces Board and Executive Changes — 8-K · Jun 3, 2025 Risk: low
  Lifeward Ltd. announced on June 2, 2025, changes in its board and executive compensation. The company, formerly known as ReWalk Robotics Ltd., filed an 8-K repo
• Lifeward Ltd. Appoints New Director, Reports Officer Compensation — 8-K · May 19, 2025 Risk: low
  Lifeward Ltd. announced on May 14, 2025, the departure of Director Dr. Alon Grode and the appointment of Dr. Yaron Bar-Tal as a new director. The company also r
• Lifeward Ltd. 10-Q: Warrant Exercises & Reverse Split Details — 10-Q · May 15, 2025 Risk: low
  Lifeward Ltd. filed its 10-Q for the period ending March 31, 2025. The filing mentions a one-for-seven reverse share split effective March 15, 2024, and details
• Lifeward Ltd. Files 8-K — 8-K · Apr 15, 2025 Risk: low
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed an 8-K on April 15, 2025, reporting other events and financial statements. The company, incorporated in Isra
• Lifeward Ltd. Announces Executive & Board Changes — 8-K · Apr 14, 2025 Risk: medium
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) announced on April 8, 2025, changes in its executive team and board of directors. The company also reported on its
• 10-K Filing — 10-K · Mar 7, 2025
• Lifeward Ltd. Files 8-K on Financials and Personnel Changes — 8-K · Feb 20, 2025 Risk: medium
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed an 8-K on February 20, 2025, reporting on results of operations and financial condition, as well as changes
• Lifeward Ltd. S-1/A Filing — S-1/A · Feb 14, 2025 Risk: medium
  Lifeward Ltd. filed an S-1/A on February 14, 2025, detailing a one-for-seven reverse share split effective March 15, 2024. The filing also mentions warrants gra
• Lifeward Ltd. Files S-1, Former ReWalk Robotics — S-1 · Feb 11, 2025 Risk: medium
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) has filed an S-1 form with the SEC. The company, specializing in orthopedic, prosthetic, and surgical appliances,
• Lifeward Ltd. Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Lifeward Ltd. filed an 8-K on January 13, 2025, to report other events and financial statements. The company, formerly known as ReWalk Robotics Ltd., is based i
• Lifeward Ltd. Files 8-K/A Amendment — 8-K/A · Jan 8, 2025 Risk: low
  Lifeward Ltd. filed an amendment (8-K/A) on January 8, 2025, to its current report originally filed on January 7, 2025. This amendment pertains to financial sta
• Lifeward Ltd. Files Proxy Materials — DEFA14A · Dec 27, 2024 Risk: low
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed a Definitive Additional Materials proxy statement on December 27, 2024. This filing relates to the company's
• Lifeward Ltd. Files Definitive Proxy Statement — DEF 14A · Nov 25, 2024 Risk: low
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed a Definitive Proxy Statement (DEF 14A) on November 25, 2024. This filing is a standard proxy statement relat
• Lifeward Ltd. Files 10-Q, Details Financials — 10-Q · Nov 12, 2024 Risk: medium
  Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational
• Lifeward Ltd. Reports Board Changes and Officer Compensation — 8-K · Nov 7, 2024 Risk: low
  Lifeward Ltd. announced on November 2, 2024, a change in its board of directors, with the departure of two directors and the election of two new directors. The
• ReWalk Robotics Ltd. Announces Executive and Board Changes — 8-K · Sep 4, 2024 Risk: medium
  On September 4, 2024, ReWalk Robotics Ltd. filed an 8-K report detailing several key events. The company announced the appointment of Dr. Alon S. Ziv as Chief M
• ReWalk Robotics Files Additional Proxy Materials — DEFA14A · Aug 26, 2024 Risk: low
  ReWalk Robotics Ltd. filed a Definitive Additional Materials filing (DEFA14A) on August 26, 2024. This filing is an amendment to their proxy statement, indicati
• ReWalk Robotics Files 8-K on Financials — 8-K · Aug 15, 2024 Risk: medium
  ReWalk Robotics Ltd. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
• ReWalk Robotics Files 10-Q, $4.6M Warrant Exercise — 10-Q · Aug 14, 2024 Risk: medium
  ReWalk Robotics Ltd. filed a 10-Q for the period ending June 30, 2024. The filing details financial information and business operations. Notably, as of March 31
• ReWalk Robotics Files Proxy Statement — DEFA14A · Aug 9, 2024 Risk: low
  ReWalk Robotics Ltd. filed a Definitive Proxy Statement (DEFA14A) on August 9, 2024. This filing is related to the company's annual meeting and likely concerns
• ReWalk Robotics Ltd. Executive Compensation Details — DEF 14A · Jul 29, 2024 Risk: medium
  ReWalk Robotics Ltd. filed a DEF 14A, detailing executive compensation for its PEO, Larry Jasinski, and Non-PEO NEOs. The filing specifies that the 'Compensatio
• ReWalk Robotics Appoints Dr. Alon Wolf as CEO — 8-K · Jul 2, 2024 Risk: medium
  ReWalk Robotics Ltd. announced on June 27, 2024, the appointment of Dr. Alon Wolf as Chief Executive Officer, effective immediately. Dr. Wolf, who has been with
• ReWalk Robotics Ltd. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: medium
  ReWalk Robotics Ltd. (LFWD) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. ReWalk Robotics Ltd. filed a 10-Q for the period ending March 31, 2024
• ReWalk Robotics Ltd. Files Amended 10-K for Fiscal Year Ended December 31, 2023 — 10-K/A · Apr 29, 2024 Risk: low
  ReWalk Robotics Ltd. (LFWD) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. ReWalk Robotics Ltd. filed an amended 10-K report for the fis
• ReWalk Robotics Appoints New CFO, Oriella Transitions — 8-K · Apr 19, 2024 Risk: medium
  On April 18, 2024, ReWalk Robotics Ltd. announced the appointment of Ms. Yafit Arnon as its new Chief Financial Officer, effective May 1, 2024. Ms. Arnon will s
• ReWalk Robotics Prices $15M Direct Offering — 8-K · Apr 4, 2024 Risk: medium
  ReWalk Robotics Ltd. announced on April 3, 2024, that it has entered into a securities purchase agreement to sell approximately $15.0 million of its ordinary sh
• ReWalk Robotics Raises $20M in Direct Offering — 8-K · Apr 3, 2024 Risk: medium
  ReWalk Robotics Ltd. announced on April 3, 2024, that it has entered into a securities purchase agreement with institutional investors for a registered direct o
• ReWalk Robotics Ltd. Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
  ReWalk Robotics Ltd. (LFWD) filed a Annual Report (10-K) with the SEC on February 27, 2024. ReWalk Robotics Ltd. filed its annual report on Form 10-K for the fi
• ReWalk Robotics Files 8-K, Confirms NASDAQ Listing for LFWD — 8-K · Jan 30, 2024
  ReWalk Robotics Ltd. filed an 8-K on January 30, 2024, reporting an 'Other Event' that occurred on January 29, 2024. The filing primarily serves to update admin

Risk Profile

Risk Assessment: Of LFWD's 41 recent filings, 3 were flagged as high-risk, 22 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Lifeward LTD.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $16,953,000
• Net Income: -$14,566,000
• EPS: -$1.16
• Debt-to-Equity: 0.82
• Cash Position: $1,956,000
• Operating Margin: N/A
• Total Assets: $23,168,000
• Total Debt: $10,413,000

Key Executives

• Joseph Turk
• Mark Grant
• William Mark Grant
• Larry Jasinski
• Dr. Alon Grode
• Dr. Yaron Bar-Tal
• Dr. Alon S. Ziv
• Ms. Yael G. Bar-Lev
• Mr. David M. Rehen
• Mr. Jonathan M. Miller
• Dr. Alon Wolf
• Moshe Shoham
• Yafit Arnon
• Oriella

Industry Context

Lifeward Ltd. operates in the biotechnology or medical device sector, where maintaining compliance with stock exchange listing requirements is crucial for investor confidence and access to capital. Companies in this space often face pressure to demonstrate growth and stability, making corporate actions like reverse splits a tool to manage share price and market perception.

Top Tags

executive-compensation (5) · SEC Filing (5) · Medical Devices (5) · 10-Q (5) · corporate-governance (5) · 8-K (4) · governance (4) · board-changes (4) · financials (4) · financial-reporting (4)

Key Numbers

• Reverse share split ratio range: 1-for-2 to 1-for-12 — Board authorized to set ratio for Proposal 1
• Ordinary shares outstanding: 18,293,776 — As of the November 26, 2025 record date, entitled to vote
• Par value per ordinary share: NIS 1.75 — Current par value, subject to elimination under Proposal 3
• Extraordinary General Meeting date: January 6, 2026 — Shareholders will vote on proposals
• Meeting start time: 10:00 a.m. EST — Time of the Extraordinary General Meeting
• Meeting location: 200 Donald Lynch Blvd., Marlborough, MA 01752 — Company's offices where the meeting will be held
• Revenues: $16.953M — Decreased from $18.118M in 2024 for the nine months ended September 30
• Net Loss: $14.566M — Increased from $13.664M in 2024 for the nine months ended September 30
• Cash and Cash Equivalents: $1.956M — Decreased from $6.746M at December 31, 2024
• Net Cash Provided by Financing Activities: $8.425M — Raised through equity offerings for the nine months ended September 30, 2025
• Impairment Charges: $2.783M — Recorded for the nine months ended September 30, 2025
• Ordinary Shares Outstanding: 17,732,137 — As of November 12, 2025
• Net Loss Per Share (Q3 2025): $0.20 — Improved from $0.35 in Q3 2024
• Net Loss Per Share (YTD 2025): $1.16 — Improved from $1.58 in YTD 2024
• Gross Profit: $4.633M — Increased from $4.152M in H1 2024, despite revenue decline.

Related Companies

RWLK · LW

Frequently Asked Questions